Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 2:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 84 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: midazolam hydrochloride syrup Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin

NCT05541471
View directory record Official record
Conditions
Pain
Interventions
VX-548, Midazolam, Digoxin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 1, 2026, 2:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants

NCT02617810
View directory record Official record
Conditions
Healthy
Interventions
JNJ-42847922, Midazolam, Warfarin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Sep 1, 2026, 2:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

CP-690,550 and Midazolam Drug-Drug Interaction Study

NCT00902460
View directory record Official record
Conditions
Healthy Volunteer
Interventions
midazolam; CP-690,550 + midazolam, CP-690,550 + midazolam; midazolam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 12, 2009 · Synced Sep 1, 2026, 2:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mechanisms Underlying Drug-Diet Interactions

NCT01034124
View directory record Official record
Conditions
Pharmacokinetics
Interventions
warfarin, vitamin K, midazolam
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 16, 2009 · Synced Sep 1, 2026, 2:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-drug Interaction Study of Gepotidacin

NCT04493931
View directory record Official record
Conditions
Infections, Bacterial
Interventions
Gepotidacin, Cimetidine, Rifampicin, Midazolam, Digoxin, Placebo matching to gepotidacin
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Sep 1, 2026, 2:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate

NCT02010970
View directory record Official record
Conditions
Healthy Volunteers, Pharmacologic Action
Interventions
Group 1 AZD3293, Group 2 AZD3293, Group 3 AZD3293, Group 1 Itraconazole, Group 2 Diltiazem, Group 3 Midazolam
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2014 · Synced Sep 1, 2026, 2:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Study of Qualaquin and Midazolam

NCT00785486
View directory record Official record
Conditions
Healthy
Interventions
Midazolam Alone, Qualaquin (quinine) alone steady state, Midazolam and Qualaquin at steady state
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 30, 2012 · Synced Sep 1, 2026, 2:15 PM EDT
Completed Phase 1 Interventional

Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam

NCT02082665
View directory record Official record
Conditions
Cancer
Interventions
Rosuvastatin10 mg tablet, Midazolam 3 mg syrup, Dabrafenib 75 mg capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 23, 2017 · Synced Sep 1, 2026, 2:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Effect of Cefiderocol on the Pharmacokinetics (PK) of Midazolam in Healthy Participants

NCT05395104
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Midazolam, Cefiderocol
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 1, 2026, 2:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects

NCT04138836
View directory record Official record
Conditions
Healthy Participants
Interventions
BBT-877, Midazolam, Itraconazole, Esomeprazole
Drug
Lead sponsor
Bridge Biotherapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 1, 2026, 2:15 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

NCT07372625
View directory record Official record
Conditions
TP53 Y220C Mutation, Advanced Solid Tumors
Interventions
metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet, midazolam hydrochloride syrup, rezatapopt
Drug
Lead sponsor
PMV Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Denver, Colorado • Orlando, Florida • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 1, 2026, 2:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy Participants

NCT05338476
View directory record Official record
Conditions
Healthy
Interventions
Midazolam, Selpercatinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 1, 2026, 2:15 PM EDT
Completed Phase 1 Interventional

A Drug-drug Interaction Study of Avapritinib and Midazolam

NCT04908176
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors, GIST, Non-resectable Advanced Solid Tumors, Recurrent or Unresectable Central Nervous System (CNS) Tumors
Interventions
Avapritinib, midazolam
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Jacksonville, Florida • Ann Arbor, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 1, 2026, 2:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-drug Interaction Study to Investigate the Pharmacokinetic Interactions Between CKD-508, Midazolam, and Rosuvastatin in Healthy Adult Male Participants

NCT06979973
View directory record Official record
Conditions
Healthy
Interventions
Midazolam, Rosuvastatin, CKD-508 Tablet
Drug
Lead sponsor
Chong Kun Dang Pharmaceutical
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 1, 2026, 2:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers

NCT01162486
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
Rifampin & midazolam, rifapentine and midazolam
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Sep 1, 2026, 2:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects

NCT01489943
View directory record Official record
Conditions
Crohn's Disease
Interventions
GSK1605786 500 mg, Midazolam 3 mg, Pioglitazone 15 mg, Omeprazole 40 mg, Rosuvastatin 10 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Sep 1, 2026, 2:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

NCT02406261
View directory record Official record
Conditions
Healthy
Interventions
Lanabecestat, Simvastatin, Midazolam, Donepezil
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Sep 1, 2026, 2:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults

NCT05526911
View directory record Official record
Conditions
Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
Interventions
TBAJ-876, Midazolam, Digoxin
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 1, 2026, 2:15 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

NCT05355701
View directory record Official record
Conditions
Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma, Advanced Colorectal Cancer (Part 1)
Interventions
PF-07799933, binimetinib, cetuximab, midazolam, fluorouracil, leucovorin, oxaliplatin
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
31
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 1, 2026, 2:15 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

NCT03358706
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
Ustekinumab IV Infusion, Ustekinumab SC Injection, Midazolam 2 mg, Warfarin 10 mg, Vitamin K 10 mg, Omeprazole 20 mg, Dextromethorphan 30 mg, Caffeine 100 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
3
States / cities
Cypress, California • Miami Springs, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Sep 1, 2026, 2:15 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours

NCT04958226
View directory record Official record
Conditions
Solid Tumour
Interventions
Capivasertib, Midazolam
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Aurora, Colorado • Durham, North Carolina • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Sep 1, 2026, 2:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study to Evaluate the Effect of Vapendavir on the Pharmacokinetics of Midazolam in Healthy Male and Female Volunteers

NCT02204501
View directory record Official record
Conditions
Drug-Drug Interaction Healthy Volunteers
Interventions
Midazolam 5mg Syrup, Vapendavir 264 mg BID, Vapendavir 528 mg QD
Drug
Lead sponsor
Biota Scientific Management Pty Ltd
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Sep 1, 2026, 2:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Testosterone Treatment on Drug Metabolism and Transport

NCT05116293
View directory record Official record
Conditions
Transgender Persons
Interventions
Midazolam oral solution, Digoxin Oral Tablet, Acetaminophen Oral Tablet
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 1, 2026, 2:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam

NCT01925911
View directory record Official record
Conditions
Healthy
Interventions
IPI-145, Midazolam
Drug
Lead sponsor
SecuraBio
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Sep 1, 2026, 2:15 PM EDT